Drug intelligence / Profile preview

IMM65

Development stage: Unknown
Lead developer: Immunova Therapeutics

Overview

IMM65 is a biological product developed by Portage Biotech as a NY-ESO-1 inhibitor. It targets the cancer/testis antigen NY-ESO-1, which is expressed in various types of cancer. IMM65 is currently in Phase 2 trials for bladder cancer and ovarian epithelial carcinoma in Canada, and in Phase 1 for solid tumors in the Netherlands.

Other names: IMM65IMM-65IMM 65PORT3PORT-3PORT 3

Targets

NY-ESO-1 (New york esophageal squamous cell carcinoma 1)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)

Beyond the preview

Go deeper on IMM65.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMM65.

Explore the full profile